Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Stem Cell Transplantation with 90 yttrium Ibritumomab Tiuxetan( 90 YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

Blood (2009) 114 (22): 868.

https://doi.org/10.1182/blood.V114.22.868.868

Published: 2009

Journal Articles

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Luhua Wang, MD, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Barry Samuels, MD, Qing Yi, MD, PhD, Barbara Pro, MD, Michelle Fanale, M.D., Jatin Shah, MD, Anas Younes, MD, Neda Bell, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Fernando Cabanillas, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 2719.

https://doi.org/10.1182/blood.V114.22.2719.2719

Published: 2009

Journal Articles

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

Constantine S. Tam, Roland Bassett, Celina Ledesma, Martin Korbling, Amin Alousi, Chitra Hosing, Partow Kebraei, Robyn Harrell, Gabriela Rondon, Sergio A. Giralt, Paolo Anderlini, Uday Popat, Barbara Pro, Barry Samuels, Frederick Hagemeister, L. Jeffrey Medeiros, Richard E. Champlin, Issa F. Khouri

Blood (2009) 113 (18): 4144–4152.

https://doi.org/10.1182/blood-2008-10-184200

Published: 2009

Journal Articles

Addition of Rituximab to Mobilization and Conditioning Overcomes the Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) Score in Patients with Relapsed FL Undergoing Autologous Stem Cell Transplantation (AUTO).

Issa F Khouri, M.D., Roland Bassett, Barry Samuels, Farzaneh Maadani, Grace-Julia Okoroji, Robyn Harrell, Martin Korbling, Leandro de Padua Silva, Amin Alousi, Chitra Hosing, Sergio Giralt, Marcos de Lima, Paolo Anderlini, Uday Popat, Rosamar Valverde, Yvonne Hsu, Fredrick Hagemeister, Peter McLaughlin, L. Jeffrey Medeiros

Blood (2008) 112 (11): 1140.

https://doi.org/10.1182/blood.V112.11.1140.1140

Published: 2008

Journal Articles

Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease.

Blood (2008) 112 (11): 1142.

https://doi.org/10.1182/blood.V112.11.1142.1142

Published: 2008

Journal Articles

Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center.

Constantine S. Tam, MBBS, Celina Ledesma, BS, Martin Korbling, MD, Luis E. Fayad, MD, Michael Wang, MD, Amin Alousi, MD, Chitra Hosing, MD, Partow Kebriaei, MD, Gabriela Rondon, MD, Sergio A. Giralt, MD, Paolo Anderlini, MD, Uday Popat, MD, Daniel Couriel, MD, Barbara Pro, MD, Barry Samuels, MD, Frederick Hagemeister, MD, Richard E. Champlin, MD, Issa F. Khouri, MD

Blood (2007) 110 (11): 484.

https://doi.org/10.1182/blood.V110.11.484.484

Published: 2007

Journal Articles

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Michael Wang, MD, Luis Fayad, MD, Frederick Hagemeister, MD, Sattva Neelapu, MD, Barry Samuels, MD, Felipe Samanigo, MD, Barbara Pro, MD, Qing Yi, MD, PhD, Neda Bell, Catriona Byrne, Pam Weaver, Kim Hartig, Robert Knight, MD, Jerry Zeldis, MD, Larry Kwak, MD, PhD, Jorge Romaguera, MD

Blood (2007) 110 (11): 2562.

https://doi.org/10.1182/blood.V110.11.2562.2562

Published: 2007

Journal Articles

Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Michael Wang, MD, Yasuhiro Oki, MD, Barbara Pro, MD, Jorge Enrique Romaguera, MD, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Frederick Hagemeister, MD, Sattva Neelapu, MD, Donald Podoloff, MD, Barry Samuels, MD, Evelyne Loyer, MD, Yuhong Zhou, MD, Anas Younes, MD

Blood (2006) 108 (11): 2714.

https://doi.org/10.1182/blood.V108.11.2714.2714

Published: 2006

Journal Articles

Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease.

Issa F. Khouri, MD, Rima M. Saliba, PhD, Ming-Sheng Lee, MD, Grace-Julia Okoroji, Luis Fayad, MD, Farzaneh Maadani, Chitra Hosing, MD, Barry Samuels, MD, Sergio Giralt, MD, Marcos de Lima, MD, Barbara Pro, MD, Anas Younes, MD, Peter McLaughlin, MD, Larry Kwak, MD, PhD, Richard E. Champlin, MD

Blood (2005) 106 (11): 44.

https://doi.org/10.1182/blood.V106.11.44.44

Published: 2005

Journal Articles

Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Nam H. Dang, MD, PhD, Barbara Pro, MD, Fredrick B. Hagemeister, MD, Dan Jones, MD, PhD, Barry Samuels, MD, Maria A. Rodriguez, MD, Andre Goy, MD, Jorge E. Romaguera, MD, Pamela L. Walker, RN, Larry Kwak, MD, PhD, Luis Fayad, MD

Blood (2004) 104 (11): 2641.

https://doi.org/10.1182/blood.V104.11.2641.2641

Published: 2004

NARROW

Stem Cell Transplantation with 90 yttrium Ibritumomab Tiuxetan( 90 YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

Addition of Rituximab to Mobilization and Conditioning Overcomes the Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) Score in Patients with Relapsed FL Undergoing Autologous Stem Cell Transplantation (AUTO).

Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease.

Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center.

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease.

Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only